W
WAVEMAN · COMPANY
MPLT · Maplight Therapeutics, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475
← ALL COMPANIES

MPLT

MapLight Therapeutics, Inc.
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001770069
FORM 144 · 11☆ WATCH
INSIDER NET · 180D
-$27.5M
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
1
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
58
13F, latest reported quarter
REVENUE GROWTH
-
XBRL, annual
NET MARGIN
-
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$27.5M over 180 days
-$11.3M over 90 days
below 91% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
58 funds added or opened last quarter
below 52% of Pharma & Biotech
REVENUE
no revenue reported in any filing
MARGIN
no margin: this company reports no revenue to divide by
BUYBACKS
no share repurchases reported
SHORT
8.4% of shares outstanding short · 1.6 days to cover · settled 2026-07-31
more than 70% of Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
Insiders are net sellers: -$27.5M across 8 people in 180 days.
58 funds added or opened positions in the latest 13F quarter, of 108 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -28.4%
-28.4%12M
-46%+8%+63%+117%2025-102025-122026-022026-032026-052026-072026-08 2025-10-28 · Novo Holdings A/S bought $16.2M2026-05-18 · Kroeger Christopher A. sold $3.2M2026-07-15 · Kroeger Christopher A. sold $1.6M2026-07-16 · Kroeger Christopher A. sold $1.5M2026-07-16 · Kroeger Christopher A. sold $1.0M2026-04-27 · GILLIS JONATHAN sold $876.8K2026-04-27 · Kreitzer Anatol sold $866.8K2026-05-08 · Kroeger Christopher A. sold $814.1K2026-07-15 · Kroeger Christopher A. sold $682.2K2026-07-17 · GILLIS JONATHAN sold $638.2K2026-07-17 · Kroeger Christopher A. sold $635.9K2026-07-17 · Kreitzer Anatol sold $533.1K2026-04-28 · GILLIS JONATHAN sold $522.7K2026-05-06 · Lillie James Woodruff sold $478.3K2026-05-06 · Foff Erin Pennock sold $463.2K2026-05-06 · Kroeger Christopher A. sold $454.5K2026-04-27 · GILLIS JONATHAN sold $437.5K2026-05-07 · Kroeger Christopher A. sold $423.6K2026-01-29 · Malenka Robert C. sold $394.4K2026-07-16 · Foff Erin Pennock sold $334.1K2026-07-15 · Foff Erin Pennock sold $331.9K2026-07-15 · Foff Erin Pennock sold $290.6K2026-05-05 · Lillie James Woodruff sold $284.9K2026-05-05 · Setia Vishwas sold $279.4K2026-08-03 · Lillie James Woodruff sold $276.9K2026-07-16 · Kreitzer Anatol sold $273.6K2026-05-05 · Foff Erin Pennock sold $271.2K2026-05-05 · Kroeger Christopher A. sold $268.4K2026-07-15 · Foff Erin Pennock sold $258.7K2026-07-16 · GILLIS JONATHAN sold $255.9K2026-05-04 · Lillie James Woodruff sold $254.4K2026-05-04 · Setia Vishwas sold $254.2K2026-02-10 · Garnett Timothy John bought $252.7K2026-05-04 · Foff Erin Pennock sold $252.4K2026-05-04 · Kroeger Christopher A. sold $251.2K2026-05-04 · Hanson Kristopher sold $248.3K2026-04-15 · Kroeger Christopher A. sold $246.0K2026-04-27 · Kreitzer Anatol sold $241.7K2026-04-27 · Kreitzer Anatol sold $238.5K2026-05-06 · Setia Vishwas sold $238.2K2026-05-06 · Lillie James Woodruff sold $235.3K2026-04-15 · Malenka Robert C. sold $231.2K2026-08-03 · Lillie James Woodruff filed to sell $287.5K2026-07-30 · Novo Holdings A/S filed to sell $24.0M2026-07-17 · JONATHAN GILLIS filed to sell $687.4K2026-07-17 · ANATOL KREITZER filed to sell $639.2K2026-07-15 · Foff Erin Pennock filed to sell $1.8M2026-07-15 · Jonathan Gillis filed to sell $1.4M2026-07-15 · Hanson Kristopher filed to sell $625.8K2026-07-15 · Anatol Kreitzer filed to sell $1.3M2026-07-15 · Kroeger Christopher A. filed to sell $5.8M2026-07-15 · Lillie James Woodruff filed to sell $714.0K2026-07-15 · ROBERT MALENKA filed to sell $664.8K
INSIDER BUYINSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders have filed to sell — before selling.
The record shows a net $27.5M sold by insiders over 180 days, 58 funds added last quarter, $37.9M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, MapLight Therapeutics, Inc. insiders sold a net $27.5M of stock across 144 Form 4 purchases and sales, with 1 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER
FILED
SHARES
VALUE
Lillie James Woodruff
Chief Scientific Officer
SELL
2026-08-03
22,082.0
$276.9K
Cox Troy
Director
BUY
2026-07-28
15,620.0
$148.7K
GILLIS JONATHAN
CAO and Interim CFO
SELL
2026-07-17
600.0
$21.9K
GILLIS JONATHAN
CAO and Interim CFO
SELL
2026-07-17
16,969.0
$638.2K
GILLIS JONATHAN
CAO and Interim CFO
SELL
2026-07-17
900.0
$34.4K
144 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 139 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
NOVO HOLDINGS A/S
3,686,622.0 sh
$132.1M
FCPM III SERVICES B.V.
3,226,400.0 sh
$115.6M
GOLDMAN SACHS GROUP INC
1,948,312.0 sh
$69.8M
BlackRock, Inc.
1,025,134.0 sh
$36.7M
Nan Fung Group Holdings Ltd
971,253.0 sh
$34.8M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
Lillie James Woodruff
FILED 2026-08-03
$287.5K
Novo Holdings A/S
FILED 2026-07-30
$24.0M
JONATHAN GILLIS
FILED 2026-07-17
$687.4K
ANATOL KREITZER
FILED 2026-07-17
$639.2K
Foff Erin Pennock
FILED 2026-07-15
$1.8M
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
CapForce IBD Breakout Opportunities ETF
$361.0K POSITION · AS OF 2026-04-30
2.3%
Lazard US Small Cap Equity Select Portfolio
$270.3K POSITION · AS OF 2026-03-31
0.8%
Lazard Global Small Cap Equity Portfolio
$99.2K POSITION · AS OF 2026-03-31
0.7%
Janus Henderson Small Cap Growth Alpha ETF
$1.6M POSITION · AS OF 2026-04-30
0.5%
T. Rowe Price Health Care ETF
$103.9K POSITION · AS OF 2026-03-31
0.5%
Fidelity Advisor Biotechnology Fund
$6.5M POSITION · AS OF 2026-04-30
0.3%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Clinical pipeline
ClinicalTrials.gov · 6 registered trials, 4 still enrolling or running — a status change here is dated weeks before the press release
6
Phase 2
4 ACTIVE
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-12
OPERATING INCOME$-169.1M$-82.9M
NET INCOME$-161.2M$-77.6M
EPS (DILUTED)-18.56-105.38
OPERATING CASH FLOW$-138.1M$-78.8M
CASH$46.7M$38.3M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-05 ALL SYSTEMS LIVE FOR MACHINES →